1. Scrip

Women’s Health Still Key to Bayer Despite Early Research Shift

Exit Rumors Inaccurate

 
• By Kevin Grogan

The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.

Bayer cross
• Source: Bayer

Claims that Bayer AG is moving away from women’s health are not correct, the German major has told Scrip, although the space will not be a priority for its early research efforts.

Eyebrows were raised following a report by Reuters, which was subsequently taken up by a number of pharma trade publications, that stated Bayer's drug research would shift away from women's health

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Women's Health

More from Scrip

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.